Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2004 1
2008 1
2010 1
2011 1
2013 2
2014 1
2016 1
2017 2
2018 3
2019 2
2020 9
2021 7
2022 2
2023 8
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Results by year

Filters applied: . Clear all
Page 1
Mouse Models for Cancer Immunotherapy Research.
Olson B, Li Y, Lin Y, Liu ET, Patnaik A. Olson B, et al. Among authors: patnaik a. Cancer Discov. 2018 Nov;8(11):1358-1365. doi: 10.1158/2159-8290.CD-18-0044. Epub 2018 Oct 11. Cancer Discov. 2018. PMID: 30309862 Free PMC article. Review.
Pan-cancer image-based detection of clinically actionable genetic alterations.
Kather JN, Heij LR, Grabsch HI, Loeffler C, Echle A, Muti HS, Krause J, Niehues JM, Sommer KAJ, Bankhead P, Kooreman LFS, Schulte JJ, Cipriani NA, Buelow RD, Boor P, Ortiz-Brüchle NN, Hanby AM, Speirs V, Kochanny S, Patnaik A, Srisuwananukorn A, Brenner H, Hoffmeister M, van den Brandt PA, Jäger D, Trautwein C, Pearson AT, Luedde T. Kather JN, et al. Among authors: patnaik a. Nat Cancer. 2020 Aug;1(8):789-799. doi: 10.1038/s43018-020-0087-6. Epub 2020 Jul 27. Nat Cancer. 2020. PMID: 33763651 Free PMC article.
Reversal of Lactate and PD-1-mediated Macrophage Immunosuppression Controls Growth of PTEN/p53-deficient Prostate Cancer.
Chaudagar K, Hieromnimon HM, Khurana R, Labadie B, Hirz T, Mei S, Hasan R, Shafran J, Kelley A, Apostolov E, Al-Eryani G, Harvey K, Rameshbabu S, Loyd M, Bynoe K, Drovetsky C, Solanki A, Markiewicz E, Zamora M, Fan X, Schürer S, Swarbrick A, Sykes DB, Patnaik A. Chaudagar K, et al. Among authors: patnaik a. Clin Cancer Res. 2023 May 15;29(10):1952-1968. doi: 10.1158/1078-0432.CCR-22-3350. Clin Cancer Res. 2023. PMID: 36862086 Free PMC article.
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration.
Abida W, Patnaik A, Campbell D, Shapiro J, Bryce AH, McDermott R, Sautois B, Vogelzang NJ, Bambury RM, Voog E, Zhang J, Piulats JM, Ryan CJ, Merseburger AS, Daugaard G, Heidenreich A, Fizazi K, Higano CS, Krieger LE, Sternberg CN, Watkins SP, Despain D, Simmons AD, Loehr A, Dowson M, Golsorkhi T, Chowdhury S; TRITON2 investigators. Abida W, et al. Among authors: patnaik a. J Clin Oncol. 2020 Nov 10;38(32):3763-3772. doi: 10.1200/JCO.20.01035. Epub 2020 Aug 14. J Clin Oncol. 2020. PMID: 32795228 Free PMC article.
Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial.
Sharma P, Pachynski RK, Narayan V, Fléchon A, Gravis G, Galsky MD, Mahammedi H, Patnaik A, Subudhi SK, Ciprotti M, Simsek B, Saci A, Hu Y, Han GC, Fizazi K. Sharma P, et al. Among authors: patnaik a. Cancer Cell. 2020 Oct 12;38(4):489-499.e3. doi: 10.1016/j.ccell.2020.08.007. Epub 2020 Sep 10. Cancer Cell. 2020. PMID: 32916128 Free article. Clinical Trial.
Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study.
Abida W, Campbell D, Patnaik A, Bryce AH, Shapiro J, Bambury RM, Zhang J, Burke JM, Castellano D, Font A, Ganju V, Hardy-Bessard AC, McDermott R, Sautois B, Spaeth D, Voog E, Piulats JM, Pintus E, Ryan CJ, Merseburger AS, Daugaard G, Heidenreich A, Fizazi K, Loehr A, Despain D, Simmons AD, Dowson M, Go J, Watkins SP, Chowdhury S. Abida W, et al. Among authors: patnaik a. Eur Urol. 2023 Sep;84(3):321-330. doi: 10.1016/j.eururo.2023.05.021. Epub 2023 Jun 3. Eur Urol. 2023. PMID: 37277275 Clinical Trial.
Reply by Authors.
Pienta KJ, Gorin MA, Rowe SP, Carroll PR, Pouliot F, Probst S, Saperstein L, Preston MA, Alva AS, Patnaik A, Durack JC, Stambler N, Lin T, Jensen J, Wong V, Siegel BA, Morris MJ. Pienta KJ, et al. Among authors: patnaik a. J Urol. 2021 Jul;206(1):61. doi: 10.1097/JU.0000000000001698.02. Epub 2021 Apr 15. J Urol. 2021. PMID: 33853358 No abstract available.
A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with 18F-DCFPyL in Prostate Cancer Patients (OSPREY).
Pienta KJ, Gorin MA, Rowe SP, Carroll PR, Pouliot F, Probst S, Saperstein L, Preston MA, Alva AS, Patnaik A, Durack JC, Stambler N, Lin T, Jensen J, Wong V, Siegel BA, Morris MJ. Pienta KJ, et al. Among authors: patnaik a. J Urol. 2021 Jul;206(1):52-61. doi: 10.1097/JU.0000000000001698. Epub 2021 Feb 26. J Urol. 2021. PMID: 33634707 Free PMC article. Clinical Trial.
Targeting Innate Immunity in Cancer Therapy.
Rameshbabu S, Labadie BW, Argulian A, Patnaik A. Rameshbabu S, et al. Among authors: patnaik a. Vaccines (Basel). 2021 Feb 9;9(2):138. doi: 10.3390/vaccines9020138. Vaccines (Basel). 2021. PMID: 33572196 Free PMC article. Review.
Suppression of tumor cell lactate-generating signaling pathways eradicates murine PTEN/p53-deficient aggressive-variant prostate cancer via macrophage phagocytosis.
Chaudagar K, Hieromnimon HM, Kelley A, Labadie B, Shafran J, Rameshbabu S, Drovetsky C, Bynoe K, Solanki A, Markiewicz E, Fan X, Loda M, Patnaik A. Chaudagar K, et al. Among authors: patnaik a. bioRxiv [Preprint]. 2023 May 23:2023.05.23.540590. doi: 10.1101/2023.05.23.540590. bioRxiv. 2023. PMID: 37292972 Free PMC article. Updated. Preprint.
41 results